The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Open accessAbstract
BACKGROUND: SGLT2 inhibitors are strongly recommended in guidelines to treat patients with heart failure with reduced ejection fraction, but their clinical benefits at higher ejection fractions are less well established. Two large-scale trials, DELIVER and EMPEROR-Preserved, in heart failure with mildly reduced or preserved ejection fraction have been done, providing power to examine therapeutic effects on cardiovascular mortality and in patient subgroups when combined with the earlier trials in reduced ejection fraction. METHODS: We did a prespecified meta-analysis of DELIVER and EMPEROR-Preserved, and subsequently included trials that enrolled patients with reduced ejection fraction (DAPA-HF and EMPEROR-Reduced) and those admitted to hospital with worsening heart failure, irrespective of ejection fraction (SOLOIST-WHF). Using trial-level data with harmonised endpoint definitions, we did a fixed-effects meta-analysis to estimate the effect of SGLT2 inhibitors on various clinical endpoints in heart failure The primary endpoint for this meta-analysis was time from randomisation to the occurrence of the composite of cardiovascular death or hospitalisation for heart failure. We assessed heterogeneity in treatment effects for the primary endpoint across subgroups of interest. This study is registered with PROSPERO, CRD42022327527. FINDINGS: Among 12 251 participants from DELIVER and EMPEROR-Preserved, SGLT2 inhibitors reduced composite cardiovascular death or first hospitalisation for heart failure (hazard ratio 0·80 [95% CI 0·73-0·87]) with consistent reductions in both components: cardiovascular death (0·88 [0·77-1·00]) and first hospitalisation for heart failure (0·74 [0·67-0·83]). In the broader context of the five trials of 21 947 participants, SGLT2 inhibitors reduced the risk of composite cardiovascular death or hospitalisation for heart failure (0·77 [0·72-0·82]), cardiovascular death (0·87 [0·79-0·95]), first hospitalisation for heart failure (0·72 [0·67-0·78]), and all-cause mortality (0·92 [0·86-0·99]). These treatment effects for each of the studied endpoints were consistently observed in both the trials of heart failure with mildly reduced or preserved ejection fraction and across all five trials. Treatment effects on the primary endpoint were generally consistent across the 14 subgroups examined, including ejection fraction. INTERPRETATION: SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisations for heart failure in a broad range of patients with heart failure, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction or care setting. FUNDING: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These drug classes are recommended as glucose-lowering therapy for individuals with cardiovascular disease or risk factors6,7 on the basis of randomized clinical trial evidence demonstrating a reduction in cardiovascular events (SGLT2is and GLP-1RAs)14,15,16 or suggesting cardiovascular benefit (metformin and pioglitazone).17,18”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a large meta-analysis (308) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death,”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [308]
The cited source says what the claim attributes to it.
In the citing paper
“A large meta-analysis (297) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and SOLOIST-WHF trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, first hospitalization for heart failure, and all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
The cited source says what the claim attributes to it.
In the citing paper
“The findings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all five trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [535]
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“A large recent meta-analysis (227) including data from EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and Effect of Sotagli fl ozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOISTWHF) included 21,947 patients and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, fi r”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
In the citing paper
“The fi ndings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all fi ve trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Self-citationSolomon, S. D., Anavekar, N. S., Skali, H., McMurray, J. J. V., Swedberg, K. B., Yusuf, S., Granger, C. B., Michelson, E. L., Wang, D., Pocock, S., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.561423 · Cited by 873
Self-citation
Research works printed but not linked: 1
- Zannad, 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, 819, 10.1016/S0140-6736(20)31824-9 · DOI · Paper page
Cited by
Sorted by citations
Items 601–700 of 1,000
Zheng, H. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(24)00448-0 · Cited by 2
Evolution of care pathways in clinical practice guidelines for heart failure
López, R. Q., Estupiñán-Romero, F., Millán-Ortuondo, E., Bernal‐Delgado, E., & Jiménez-García, N. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.02.011 · Cited by 2
Hypertension in chronic kidney disease and future heart failure
Burnier, M. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001206 · Cited by 2
Molecular mechanisms for pathophysiology and therapy of cardiac dysfunction in heart failure
Dhalla, N. S., Elimban, V., Adameová, A., & Goyal, R. K. (2025) · Scripta Medica · doi:10.5937/scriptamed56-56443 · Cited by 2
6. Cardio-renal protection in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112150 · Cited by 4
Prescribing Antidiabetic Medications Among GPs in Croatia—A Real-Life Cross-Sectional Study
Kurevija, T., Schönberger, E., Ličanin, M. M., Bilić-Čurčić, I., Majnarić, L. T., & Canecki-Varžić, S. (2025) · Biomedicines · doi:10.3390/biomedicines13061491 · Cited by 2
Wu, C., Sharma, A., Edwards, J. D., Liu, P. P., Wu, C. F., Podolsky, S., Kapral, M. K., Lanctôt, K. L., MacIntosh, B. J., Cogo‐Moreira, H., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.05.022 · Cited by 3
Reduction in heart failure outcomes with SGLT2 inhibitors irrespective of glycaemic status
Gerstein, H. C., & Sattar, N. A. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00313-8 · Cited by 2
The year in cardiovascular medicine 2022: the top 10 papers in diabetes and metabolic disorders
Cosentino, F., Marx, N., & Verma, S. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac780 · Cited by 2
Balletti, A., Biase, N. D., Punta, L. D., Filidei, F., Armenia, S., Masi, F., Fiore, V. D., Mazzola, M., Bacca, A., Dini, F. L., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13040790 · Cited by 2
Hofer, F., Hammer, A., Steinacher, E., Baumer, U., Kazem, N., Koller, L., Richter, B., Hengstenberg, C., Sulzgruber, P., & Niessner, A. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad022 · Cited by 2
Butler, J., Siddiqi, T. J., Zannad, F. M., Ferreira, J. P., Fillipatos, G., Anker, S. D., & Packer, M. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2854 · Cited by 2
Manyari, D. E., Belenkie, I., & Quiroz, O. G. (2023) · Springer eBooks · doi:10.1007/978-3-031-17650-0_31 · Cited by 2
Khiali, S., Sadeghi, M. T., Sarbakhsh, P., Khezerlouy‐Aghdam, N., Namdar, H., Salehi, R., Rezagholizadeh, A., & Entezari‐Maleki, T. (2023) · Trials · doi:10.1186/s13063-023-07682-6 · Cited by 2
de la SEC, G. D. T. D. L. S. P. L. A. 2. D. L. G. E. 2. S. E. D. Y. T. D. L. I. C. A. Y. C. Y. C. D. G. (2024) · Revista Española de Cardiología · doi:10.1016/j.recesp.2023.10.021 · Cited by 2
Current Place of SGLT2i in the Management of Heart Failure: An Expert Opinion from India
Chopra, H. K., Nair, T., Wander, G. S., Ponde, C. K., Ray, S., Khullar, D., Nanda, N. C., Narula, J., Kasliwal, R. R., Rana, D. S., et al. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.71.0440 · Cited by 2
Campbell, R. T., & Docherty, K. F. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad209 · Cited by 2
Self-citationMacDonald, B. J., & Turgeon, R. D. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.05.018 · Cited by 2
Docherty, K. F., & McMurray, J. J. V. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102763 · Cited by 2
Self-citationAdie, S. K., & Konerman, M. C. (2023) · Annals of Internal Medicine · doi:10.7326/m23-0588 · Cited by 1
Karaca, O. (2023) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2023.25425 · Cited by 1
Perioperative Management of Novel Pharmacotherapies for Heart Failure and Pulmonary Hypertension
Gross, C. R., Varghese, R., & Zafirova, Z. (2023) · Anesthesiology Clinics · doi:10.1016/j.anclin.2023.09.004 · Cited by 1
Lessons learned from early-stage clinical trials for diabetic nephropathy
Rendell, M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326025 · Cited by 1
Hypertension artérielle et insuffisance cardiaque
Saadi, M. (2024) · Archives des Maladies du Coeur et des Vaisseaux - Pratique · doi:10.1016/j.amcp.2024.03.006 · Cited by 1
Larina, V. N., & Васильевна, Л. М. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-129 · Cited by 1
Bedeutung der Insulintherapie bei Menschen mit Diabetes mellitus Typ 2
Jecht, M., Dötsch, I., & Häussler, R. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01236-3 · Cited by 1
Wada, S., Iwanaga, Y., Nakai, M., Noguchi, T., & Miyamoto, Y. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108908 · Cited by 1
SGLT2 Inhibitors in Cardiovascular Medicine: Panacea or Pandora’s Box?
Ferreira, S. D. A. T., de Oliveira, L. L. H., de Assis, A. C. R., Soares, P. R., & Scudeler, T. L. (2024) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0546 · Cited by 1
Para, O., Vanetti, M., Dibonaventura, C., Salerno, D., Caruso, L., Carleo, C., Raza, A., Nozzoli, C., & Spanevello, A. (2025) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2025.3157 · Cited by 1
Heart Rate Reduction and the Prognosis of Heart Failure Focused on Ivabradine
Kiuchi, S., & Ikeda, T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041074 · Cited by 2
Hong, D., Hong, M., Kim, O., Shin, H.-Y., Bak, M., Kim, D., Kim, J., Choi, K. H., Kim, E. K., Lee, J. M., et al. (2025) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2025.02.007 · Cited by 1
Luo, J.-C., Jin, L.-H., Zhong, Y.-S., Xu, X., Zhang, Z.-Y., Chen, J., Chen, Z.-X., Li, S., Zhang, X.-D., & Qian, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114631 · Cited by 1
Chen, L., Zhang, D., Zheng, Y., Xue, J., Zhang, Q., Deng, Z., Mazhar, M., Zou, Y., Liu, P., Chen, M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-00088-1 · Cited by 1
Wolf, P. J. W., Correia, E. B., Neto, J. M. R., Finger, M. A., dos Santos, C. C., de Vasconcellos, M. A. B., Bruscky, L. V. R., Murta, A. C. D. S., Francisco, Y. A., Albrecht, F. C., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20240676i · Cited by 1
Effects of sodium-glucose cotransporter 2 inhibitors on cardiomyopathy: a meta-analysis
Xu, B., Zhang, T., & Zhou, J. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02625-1 · Cited by 1
Kelemen, H., Mărcuțiu, P.-E., & Adrienn, R. (2023) · Orvostudományi Értesítö · doi:10.2478/orvtudert-2023-0009 · Cited by 1
Karczmarska‐Wódzka, A., Wszelaki, P., Pstrągowski, K., & Sikora, J. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155500 · Cited by 1
Okumura, T., Kusunose, K., Tsuji, T., Kotoku, J., Todaka, K., & Saku, K. (2025) · Cardiology Discovery · doi:10.1097/cd9.0000000000000168 · Cited by 1
Dapagliflozin, Heart Failure, and Duration of Diabetes
Butt, J. H., de Boer, R. A., Docherty, K. F., Kondo, T., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M., Køber, L., Lam, C. S. P., Martínez, F. A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102630 · Cited by 1
Self-citationCatheter Ablation of Atrial Fibrillation in Patients With Heart Failure—Therapy or Futility?
Golan, Y. B.-B., & Lambiase, P. D. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0870 · Cited by 1
Metabolic syndrome and heart failure
Lopatin, Y. M. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6540 · Cited by 1
The Timeline of the Association Between Diabetes and Cardiovascular Diseases: A Narrative Review
Luca, S. A., Bungau, R. M., Lazăr, S., Herascu, A., Gaiţă, L., Avram, V. F., & Timar, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196877 · Cited by 1
Do Heart Failure With Preserved Ejection Fraction Treatments Work by Targeting Adipose Biology?
Borlaug, B. A. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.046 · Cited by 1
Özgöl, İ., YİĞİT, E., Yıldız, C., Karabulut, D., Çağlar, F. N. T., Bicakhan, B., Yücel, C., Ketenciler, S., Ay, A., & Yiğit, Z. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207395 · Cited by 1
Safety and Efficacy of Salt Restriction Across the Spectrum of Heart Failure
Stachteas, P., Nasoufidou, A., Koiliari, M., Arampatzi, V., Alexaki, C., Kofos, C., Karakasis, P., Karagiannidis, E., Koufakis, T., Fragakis, N., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12110432 · Cited by 1
Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus
An, X., Li, X., Zhang, H., Jia, Q.-Y., Zhang, Y., & Yang, G.-G. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i11.111280 · Cited by 1
Saraiva, J. F. K., Valério, C. M., Rached, F. H., van de Sande‐Lee, S., Rocha, V. Z., Valente, F., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250621 · Cited by 9
Management of HFpEF in Asian Patients
Hung, C., Chiang, C., & Yeh, H.-I. (2025) · JACC Asia · doi:10.1016/j.jacasi.2025.09.014 · Cited by 1
Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure (SiN-HF)
Savage, P., Linden, K., Dixon, L., Grieve, D., & Watson, C. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07800-3 · Cited by 1
Larina, V. N. (2025) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-4-2025-448-459 · Cited by 1
Lei, Y., Li, B., Gosse, T., Cho, S., Sung, H. K., Chen, J., & Sweeney, G. (2026) · Metabolites · doi:10.3390/metabo16010038 · Cited by 1
Sex Differences in Antiarrhythmic Effects of Empagliflozin
Nakano, M., Kondo, Y., Fujiki, S., Shiko, Y., Kawasaki, Y., Nakagawa, Y., Takahashi, K., Okabe, M., KUSANO, K. F., Owada, S., et al. (2026) · JACC Asia · doi:10.1016/j.jacasi.2025.11.017 · Cited by 1
Fazio, S., & Carlomagno, G. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1719492 · Cited by 3
Badr, A., Suppah, M., Awad, K., Abbas, M. T., Abdullah, H. A., Arsanjani, R., Ayoub, C., & Alsidawi, S. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.12.014 · Cited by 1
Verelst, F. R., Witte, K. K., Ahmed, F. Z., Al‐Khatib, S. M., Parkash, R., Gevaert, A. B., & Spall, H. G. C. V. (2026) · Heart · doi:10.1136/heartjnl-2025-326954 · Cited by 1
Doku, A., EL‐HARARI, M. B., Badr, A., Bennis, A., Ogola, E. N., AlHabeeb, W., Abdelhamid, M., & Mbakwem, A. C. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.043650 · Cited by 1
Yang, J., Li, X., Tang, L., Fan, W., Li, A., Zhou, W., Pang, J., Yuan, Q., Zhong, M., Hou, J., et al. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05757-1 · Cited by 1
Obesity and Heart Failure: Introducing the Theme
Monitillo, F., Basile, P., & Lisco, G. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13040153 · Cited by 2
Alhamdan, Y. R., Hsu, J. C., & Lu, C. Y. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70718 · Cited by 1
Bian, E., Zou, W.-W., Zhu, Q.-K., Zhuang, W.-Z., Chen, J.-M., Cen, J., & Gao, Q. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-04141-6 · Cited by 1
Ahmed, M., Rana, J. S., Sajjad, L., Zulfiqar, E., Chandak, V. R., AIN, Q. T., Ahmed, R., Mentz, R. J., & Fonarow, G. C. (2026) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2026.04.018 · Cited by 1
Mori, M., Ailawadi, G., Bolling, S. F., Hahn, R. T., Kaneko, T., Killu, A. M., Lee, A. M., McCarthy, P. M., Mick, S., Praz, F., et al. (2026) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2026.03.621 · Cited by 1
Wu, C., Shah, B. R., Ezekowitz, J. A., Sharma, A., Wang, T., Wu, C. F., Liu, P. P., Edwards, J. D., & Swardfager, W. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag031 · Cited by 1
Lund, L. C., Simonsen, E., & Pottegård, A. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113341 · Cited by 1
Valvular Heart Disease in Heart Failure with Preserved Ejection Fraction
Adeli, A., Sampath-Kumar, R., Wang, A., Manouras, A., Savarese, G., Hahn, R. T., Lund, L. H., & Shahim, B. (2026) · Cardiac failure review · doi:10.15420/cfr.2025.13 · Cited by 1
Tomasoni, D., Benson, L., Butler, J., Guidetti, F., Melin, M., Cabrera, C. C., Metra, M., Lund, L. H., & Savarese, G. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag041 · Cited by 1
Guan, S., Sun, X., Huang, Y., Li, Y., Wang, J., Chen, J., Yang, Y., Li, X., Zhang, Y., Meng, C., et al. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118159 · Cited by 1
Alfehaid, L., Alkhezi, O. S., Alrayes, R., Alsuwaylihi, A., Alharbi, A. I., Aldosari, B., & Badreldin, H. A. (2026) · Cardiology and Therapy · doi:10.1007/s40119-026-00458-4 · Cited by 1
Yang, D. X., Thakur, S., Akunor, H., Stacey, R. B., & Upadhya, B. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13070291 · Cited by 1
Lee, J. M., Kim, Y., Lee, S. Y., Kwon, W., Hwang, D., Chon, M. K., Joh, H. S., Lee, S. H., Lee, K. Y., Seo, Y. H., et al. (2026) · Korean Circulation Journal · doi:10.4070/kcj.2026.0191 · Cited by 1
Jiang, Y., Jia, S., tian, D., Qiang, H., Zhao, H., Chen, X., Su, X., & Jia, X. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07904-4 · Cited by 2
Tariq, N., Islam, A. K. M. R., Dhadke, P., Patel, T., Muhammad, M. R., Aawesh, M., Muhammad, S. R., & Tahir, B. (2026) · Exploration of Cardiology · doi:10.37349/ec.2026.1012113 · Cited by 1
Monzo, L., Hanon, O., Savarese, G., Fauvel, C., Berthelot, E., Seronde, M., Assyag, P., Esser, R., Picard, F., Pages, N., et al. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134683 · Cited by 1
Concomitant use of SGLT2 inhibitors and GLP-1 receptor agonists in patients with heart failure
Khademi, R., & Shoar, S. (2026) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-026-00319-y · Cited by 1
Verbrugge, F. H., Vachiery, J. E., & Müllens, W. (2026) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2026.2704798 · Cited by 1
Incretin analogues as cardiovascular agents: a state-of-the-art review
Garaygordobil, D. A., Rico-Fontalvo, J. E., Hernández-Balbuena, B., Vinay, M., & Gonzalez-Arias, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1898812 · Cited by 1
Dapagliflozin in Patients With Heart Failure Across the Care Spectrum
Berg, D. D., Vaduganathan, M., Docherty, K. F., Bellavia, A., Murphy, S. A., Claggett, B. L., Desai, A. S., Inzucchi, S. E., Patel, S. M., Wiviott, S. D., et al. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103232 · Cited by 1
Self-citationJurin, I., Hanžek, A., Lišnjić, P., & Jakljević, T. (2026) · Acta Clinica Belgica · doi:10.1080/17843286.2026.2719667 · Cited by 1
Cardiovascular risk management in the elderly: a dilemma in daily clinical practice
Dacquino, G. M., Galati, G., Genovese, L., Bravo, F. F., Bernardi, M., Spadafora, L., & Pedretti, R. F. E. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag316 · Cited by 1
Euglycemic ketoacidosis in a nondiabetic patient receiving dapagliflozin for heart failure
Silveira, G., Kvasha, Y., Shah, P., Shah, H., & Gogineni, J. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag275 · Cited by 1
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Sethi, S. M., Umer, A., Batool, Z., Jitender, K., Baloch, F., & Arshad, A. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0099 · Cited by 1
HFpEF in Japan: When an Epidemiological Transition Becomes an Epidemiological Opportunity
Mitter, S. S., & Shah, S. J. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.02.005 · Cited by 1
Self-citationSodium-glucose cotransporter 2 inhibitors in Asian patients with heart failure
Kato, S., Horita, N., & Utsunomiya, D. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002652 · Cited by 1
Exploring the Comparative Roles of a Canadian Primary Care and Tertiary Care Heart Function Clinic
Geukers, K., Hinton, S., Heckman, G. A., Harkness, K. I., Suskin, N., Hartley, T., Lonn, E., Korseed, S., & McKelvie, R. S. (2023) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v18i2.681 · Cited by 1
Guan, X., Zhang, J., Chen, G., Zhang, G., Chang, S.-T., Nie, Z., Liu, W., Guo, T., Zhao, Y., & Li, B. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10330-5 · Cited by 1
Los inhibidores SGLT2: una mirada al futuro del tratamiento de la insuficiencia cardiaca
Nouel, A., Winter, J. L., & Sepúlveda, L. (2022) · Revista médica de Chile · doi:10.4067/s0034-98872022001201647 · Cited by 1
Controversies and dilemmas in the diagnosis of heart failure with preserved ejection fraction
Prasad, S. B., Holland, D. J., & Atherton, J. J. (2023) · The Medical Journal of Australia · doi:10.5694/mja2.52053 · Cited by 2
Soh, B. W. T., Langille, J. M., O’Brien, K., Glasgow, J., Murray, S., Abbas, S., O'Connor, C. T., Arnous, S., & Kiernan, T. J. (2023) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-023-01530-z · Cited by 1
Ito, S., Koike, T., Matsushige, Y., Takasugi, K., & Kato, S. (2023) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2023.5.4.1872 · Cited by 1
Sun, Y., Fu, Q., Tse, G., Bai, L., Liu, J., He, H., Zhao, S., Tse, M. Y. M., & Liu, Y. (2023) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001578 · Cited by 1
Karlström, P., Pivodic, A., Dahlström, U., & Fu, M. L. X. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14582 · Cited by 2
Xiao, Y., & Liu, C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad408 · Cited by 1
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Ito, S., & Kato, S. (2024) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2024.6.2.2038 · Cited by 1
Stachteas, P., Patoulias, D., Popovic, D. S., Athanasiadou, P., & Fragakis, N. (2024) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2024.20.1.6 · Cited by 1
Dababneh, S., Kim, K.-H., & Tibbits, G. F. (2024) · Clinical Epigenetics · doi:10.1186/s13148-024-01721-y · Cited by 1
SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation
Lopes, A. C., Lourenço, O. M., & Morgado, M. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2421872 · Cited by 1
Ojaimi, R. E., Cheisson, G., Cosson, E., Ichaï, C., Jacqueminet, S., Catargi, B., Ouattara, A., Tauveron, I., Valensi, P. E., & Benhamou, D. (2024) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2024.101468 · Cited by 1
JACOBS, G., EMBLIN, K., Kadam, U. T., DANIELS, R., ALALLAN, M., & Mokbel, K. (2024) · In Vivo · doi:10.21873/invivo.13859 · Cited by 2
Metadata
- Authors
- Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D.
- Affiliations
- Brigham and Women's Hospital (US)
- British Heart Foundation (GB)
- Duke Medical Center (US)
- Yale University (US)
- University of Missouri–Kansas City (US)
- National University of Singapore (SG)
- Northwestern University (US)
- Corresponding author
- Solomon, Scott D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 400
- Issue
- 10354
- Pages
- 757-767
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4293353625
- Cited by
- 996
- References
- 24
- Citations by year
- 2026: 215 · 2025: 203 · 2024: 279 · 2023: 257 · 2022: 42
- FWCI
- 39.76
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-14)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, public-domain)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (acceptedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, public-domain)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company (NCT03057951)
- Pfizer
- AstraZeneca
- Sanofi
- National Institutes of Health
- Defense Acquisition Program Administration
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, all-cause mortality, subgroup analysis, DAPA-HF, EMPEROR-Preserved, EMPEROR-Reduced, cardiovascular risk stratification, treatment effect heterogeneity
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure, Hospitalization, Humans, Stroke Volume, Randomized Controlled Trials as Topic, Ventricular Function, Left, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
